Stratégies d’arrêt ou de réduction des biomédicaments dans la polyarthrite rhumatoïde en rémission

Auriane Mallick(Hopitaux Civils de Colmar), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Flora Sagez(Laboratoire National de Référence), Christelle Sordet, Emmanuel Chatelus(Laboratoire National de Référence), J.E. Gottenberg(Inserm), H. Petit(Hôpitaux Universitaires de Strasbourg), N Rahal(Hôpitaux Universitaires de Strasbourg), R.‐M. Javier(Hôpitaux Universitaires de Strasbourg), Bruno Fautrel
La Revue de Médecine Interne
February 2, 2017
10.1016/j.revmed.2016.12.014
Cited by 0

Related Papers

<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
|Blood|1997|346
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
|The Lancet Rheumatology|2021|292